SCHEMBL7035876

SCHEMBL7035876

N#Cc1ccc(S(=O)(=O)CCCN2CC3CC(C2)CN(c2nccs2)C3)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
CYP19A1 P11511 1/20 0.35
GAA P10253 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
DPP4 P27487 1/20 0.34
DPP8 Q6V1X1 1/20 0.34
DPP9 Q86TI2 1/20 0.34
DPP7 Q9UHL4 1/20 0.34
KCNA5 P22460 1/20 0.33
GRM5 P41594 1/20 0.33
GRM1 Q13255 1/20 0.33
F2 P00734 1/20 0.33
F10 P00742 1/20 0.33
HRH2 P25021 3/20 0.33
HRH1 P35367 3/20 0.33
SCN5A Q14524 1/20 0.33
SCN9A Q15858 1/20 0.33
TRPV1 Q8NER1 1/20 0.33
CYP11B1 P15538 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7035436 0.81 MEN1 (0.40) MEN1KMT2ADPP4DPP8DPP9
SCHEMBL7035992 0.81 KCNA5 (0.48) MEN1KMT2AKCNA5HRH2HRH1
SCHEMBL7034768 0.79 MKNK1 (0.46) DPP4HRH2HRH1
SCHEMBL7028285 0.78 CYP19A1 (0.38) CYP19A1HRH2HRH1HRH3
SCHEMBL6996965 0.77 SIGMAR1 (0.41) CYP19A1HRH2HRH1HRH3
SCHEMBL6997428 0.76 DRD2 (0.41) DPP4DPP8HRH2HRH1CYP11B1
SCHEMBL7033710 0.73 HRH2 (0.38) MEN1CYP19A1HRH2HRH1HRH3
SCHEMBL7034791 0.73 KDM4E (0.47) MEN1KMT2AL3MBTL1
SCHEMBL7033675 0.73 HRH2 (0.37) MEN1CYP19A1DPP4HRH2HRH1
SCHEMBL6990862 0.72 THRB (0.43) MEN1KMT2AHRH2HRH1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030212095-A1 New bispidine compounds and their use in the treatment of cardiac arrhythmias ASTRAZENECA AB (SE) 2003-11-13 US disclosed
EP-1301510-A1 NEW BISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS AstraZeneca AB (SE) 2003-04-16 EP disclosed
WO-2002004446-A1 NEW BISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS ASTRAZENECA AB (SE) 2002-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212095-A1 New bispidine compounds and their use in the treatment of cardiac arrhythmias KCNH1, LBR, CACNA1E MEN1 2260/4885KMT2A 2608/4885CYP19A1 1629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.